Revelation Biosciences, Inc. (OTCMKTS:REVB – Get Rating)'s share price was down 3.4% during mid-day trading on Wednesday . The company traded as low as $0.20 and last traded at $0.20. Approximately 235,675 shares changed hands during trading, a decline of 91% from the average daily volume of 2,684,058 shares. The stock had previously closed at $0.21.

Revelation Biosciences Price Performance

The company's fifty day simple moving average is $0.25 and its 200 day simple moving average is $0.48.

Get Revelation Biosciences alerts:

Revelation Biosciences (OTCMKTS:REVB – Get Rating) last announced its quarterly earnings results on Thursday, November 10th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.03.  On average, sell-side analysts predict that  Revelation Biosciences, Inc. will post -0.66 earnings per share for the current fiscal year.

Institutional Trading of Revelation Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Ergoteles LLC bought a new stake in shares of  Revelation Biosciences in the 1st quarter worth approximately $25,000.  State Street Corp purchased a new stake in shares of  Revelation Biosciences in the third quarter worth $28,000.  Finally, Monashee Investment Management LLC bought a new position in shares of  Revelation Biosciences during the first quarter valued at $932,000. 5.38% of the stock is owned by hedge funds and other institutional investors.

Revelation Biosciences Company Profile

(Get Rating)

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-100, a potential therapy for the prevention and treatment of healthcare-associated bacterial infection resulting from surgery, severe burns, and antibiotic resistance; REVTx-200, a potential intranasal therapy; and REVTx-300, a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis.

See Also

• Get a free copy of the StockNews.com research report on Revelation Biosciences (REVB)

• Santa Claus Rally? Here's What Needs to Happen

• Cosmos Holdings May be a Long-Term Buy with Short-Term Risk

• Dark Clouds Are Gathering For Cloud Stocks

• Hormel: Is This The Time To Buy?

Receive News & Ratings for Revelation Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revelation Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.